ALSO NOTED: FDA clears BMS' Abilify for youth use; Teva to create 165 jobs in Ireland;

> The Otsuka Pharmaceutical/Bristol-Myers Squibb antipsychotic drug Abilify got the FDA nod for use in bipolar patients 10 to 17 years old. Report

> Teva Pharmaceutical plans to create more than 165 new jobs over the next five years at its IVAX facility in Waterford, Ireland, which researches and makes respiratory products. Report

> FDA warned asthma and emphysema patients not to swallow Spiriva and Foradil capsules, which are designed to be used with inhalers rather than orally. Report

> A Massachusetts judge fined Medtronic $10 million for unacceptable tactics during a patent-infringement trial. Report

> Biovail founder--and largest shareholder--Eugene Melnyk (photo) isn't happy with the company's management, and he's going to do something about it. In a scathing letter to shareholders, Melnyk lambastes the current board of directors for, as he says, not helping the company realize the full potential of its drug delivery technology. Report

> Alnylam is offering up the first signs that RNAi therapy may work in humans. Report

> GlaxoSmithKline has halted work on Dacart after a Phase III trial showed the malaria drug causes anemia in some patients. Report

And Finally... Connecticut ranks second in the nation for its use of antipsychotic drugs in nursing home residents who don't have psychotic disorders. Report